Steroids dependent nephrotic syndrome
Reading File
Finding Sources
Searching PubMed
"steroid-dependent nephrotic syndrome" AND management
Reading File
Searching PubMed
"nephrotic syndrome" AND "steroid dependent" AND children
Reading File
Finding Sources
Reading File
Reading Article
PMID: 40254362
Now I have thorough content. Let me compile a comprehensive answer.
Steroid-Dependent Nephrotic Syndrome (SDNS)
Definition
Steroid-dependent nephrotic syndrome (SDNS) is defined as two or more consecutive relapses occurring during steroid taper or within 14 days of stopping steroids. It is a subset of steroid-sensitive nephrotic syndrome (SSNS) and is distinguished from frequent relapsing nephrotic syndrome (FRNS), in which relapses are not temporally linked to steroid withdrawal.
- FRNS: 2+ relapses within 6 months of initial response, OR 4+ relapses in any 12-month period
- SDNS: relapses during or within 14 days of stopping steroids (on 2 or more occasions)
Epidemiology and Risk Factors
Approximately 50% of children with initial SSNS will develop either FRNS or SDNS over time (Brenner and Rector's The Kidney). Risk factors for a frequent relapsing or steroid-dependent course include:
- Age under 5 years at presentation
- Male sex
- Greater number of relapses in the first 6 months of disease (strongest predictor)
- Upper respiratory tract infections - approximately 70% of relapses are preceded by a URI
Pathophysiology
The underlying mechanism is not fully characterized, but SDNS is believed to involve dysregulated T-cell immunity, particularly abnormal T-helper cell activity that leads to a putative circulating permeability factor damaging glomerular podocytes. B-cell involvement is also implicated (supported by the efficacy of rituximab). The glomerular lesion in most pediatric SSNS/SDNS is minimal change disease (MCD) on biopsy, though focal segmental glomerulosclerosis (FSGS) can be seen.
Treatment
1. Relapse Management (Oral Steroids)
Each relapse is treated with oral prednisone 2 mg/kg/day (max 80 mg/day) in divided doses until urine protein is trace/negative on dipstick for 3 consecutive days, then tapered to 1.5 mg/kg on alternate mornings for 4 weeks (ISKDC protocol), followed by gradual discontinuation.
2. Steroid-Sparing Agents
Because SDNS requires repeated steroid courses with cumulative toxicity (growth failure, obesity, hypertension, osteoporosis, cataracts), steroid-sparing agents are the mainstay of long-term management:
| Agent | Dose | Efficacy in SDNS | Key Toxicities |
|---|---|---|---|
| Cyclophosphamide | 2 mg/kg/day PO x 8-12 weeks | ~30-35% sustained remission | Leukopenia, hemorrhagic cystitis, malignancy risk, infertility |
| Chlorambucil | 0.2 mg/kg/day x 8-12 weeks | ~30-35% | Seizures, bone marrow suppression, malignancy |
| Levamisole | 2.5 mg/kg PO on alternate days | Prolongs remissions; not curative | Flu-like symptoms, neutropenia, agranulocytosis |
| Mycophenolate mofetil (MMF) | ~600 mg/m²/dose BID (max 1000 mg BID) | Good relapse reduction | Nausea, diarrhea, bone marrow suppression; no nephrotoxicity |
| Cyclosporine (CNI) | Trough-guided dosing | Effective while on drug | Nephrotoxicity, hypertension, hirsutism, gingival hyperplasia |
| Tacrolimus (CNI) | Trough-guided dosing | Similar to cyclosporine | Nephrotoxicity, neurotoxicity, diabetes |
| Rituximab | IV anti-CD20 monoclonal antibody | Achieves prolonged remission in many SDNS patients | Infusion reactions, hypogammaglobulinemia, PML (rare) |
- Alkylating agents (cyclophosphamide, chlorambucil) are only ~30-35% effective in SDNS, compared to ~75% in FRNS, due to the stronger steroid dependence; their use is declining given significant toxicities.
- Levamisole acts as an immunostimulant (unique among NS treatments - all others are immunosuppressive) and can reduce steroid exposure, though its effects do not persist beyond the treatment period.
- MMF and mizoribine have become popular due to their effectiveness, modest side-effect profiles, and the absence of renal toxicity.
- CNIs (cyclosporine, tacrolimus) are highly effective but are associated with nephrotoxicity, which limits long-term use; disease frequently relapses when the drug is stopped.
- Rituximab (anti-CD20) achieves durable steroid-free remissions in a significant proportion of SDNS patients and has become a widely used option. A 2023 study showed obinutuzumab (a next-generation anti-CD20) as a promising option in rituximab-refractory SDNS (Dossier et al., CJASN 2023).
3. KDIGO 2025 Guidance
The KDIGO 2025 Clinical Practice Guideline (published May 2025) updated the treatment algorithm for children with nephrotic syndrome. It now provides clearer guidance on:
- When to perform kidney biopsy and/or genetic testing
- Choice of glucocorticoid-sparing agent (CNI, oral cyclophosphamide, levamisole, MMF, rituximab) based on patient resources, adherence, adverse effect profile, and patient/family preferences
A 2025 RCT in JAMA Pediatrics (Wang et al., PMID 40354041) directly compared tacrolimus vs. MMF for frequently relapsing or SDNS, providing fresh evidence to guide this specific clinical choice.
Monitoring and Complications
Steroid toxicity monitoring is essential in SDNS due to cumulative exposure:
- Height and weight (growth failure)
- Blood pressure (hypertension)
- Blood glucose (steroid-induced diabetes)
- Eye exam (posterior subcapsular cataracts, glaucoma)
- DEXA scan (osteoporosis)
- Infection surveillance (particularly varicella, pneumococcal disease)
Disease complications include:
- Thromboembolism (hypercoagulable state from urinary antithrombin III loss)
- Infections (hypogammaglobulinemia from urinary immunoglobulin loss)
- Hyperlipidemia
- Edema and hypoalbuminemia during relapses
Summary Table
| Feature | SDNS |
|---|---|
| Definition | Relapse on/within 14 days of stopping steroids, on 2+ occasions |
| Typical histology | Minimal change disease (MCD) |
| Initial treatment | Prednisolone per ISKDC protocol |
| 1st-line steroid-sparing | Levamisole, MMF, low-dose CNI, or rituximab |
| 2nd-line | Rituximab, obinutuzumab, or combination therapy |
| Alkylating agents | Less effective in SDNS (~30-35%), declining use |
| Prognosis | Most achieve long-term remission; ~10-20% progress to SRNS |
Note: The KDIGO 2025 guidelines represent the most current evidence-based framework for managing these children. The choice of steroid-sparing agent should be individualized based on efficacy, toxicity, cost, and patient factors.
Source: Brenner and Rector's The Kidney, Chapter 72 (Pediatric Nephrotic Syndrome); KDIGO 2025 Guideline (PMID 40254362)
This is a shared conversation. Sign in to Orris to start your own chat.